This website is intended for healthcare professionals only

Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue reflects the growing momentum of precision oncology, from liquid biopsy and response-adapted strategies to antibody–drug conjugates (ADCs) and immune-based therapies, alongside the challenges of translating these advances into routine, equitable care. We open with an editorial […]

Ian W Flinn, ASCO 2018 – Recent advances in relapsed/refractory CLL, DLBCL & follicular lymphoma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 12th 2018

Editorial board member, Ian W Flinn from Sarah Cannon, Tennesse Oncology, in Nashville, TN, talks to us about risk of relapse and promising treatments for relapsed/refractory CLL and advances in the treatment of DLBCL and follicular lymphoma.

1. What are the most important unmet needs in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)? (0:11)

2. What do you consider the most promising treatments in clinical development for relapsed/refractory CLL? (0:51)

3. Can we predict in advance who is at high-risk to relapse and then modify therapy for these high-risk patients? (1:42)

4. What have been the most exciting recent developments in the treatment of diffuse large B-cell lymphoma (DLBCL)? (2:34)

5. What are the most exciting developments in the frontline treatment of follicular lymphoma? (3:26)

Speaker disclosures: Ian W Flinn has nothing to disclose in relation to this video interview.

Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup